Melanoma neoantigen vaccines: Are we getting more personal now?

Details

Request a copyRequest a copy
Serval ID
serval:BIB_362339C5E2F1
Type
Article: article from journal or magazin.
Collection
Publications
Institution
UNIL/CHUV
Title
Melanoma neoantigen vaccines: Are we getting more personal now?
Journal
Med
Author(s)
Latifyan S., Haanen J.B.
ISSN
2666-6340 (Electronic)
ISSN-L
2666-6340
Publication state
Published
Issued date
12/04/2024
Peer-reviewed
Oui
Volume
5
Number
4
Pages
288-290
Language
english
Notes
Publication types: Clinical Trial, Phase II ; Randomized Controlled Trial ; Journal Article
Publication Status: ppublish
Abstract
KEYNOTE-942 <sup>1</sup> is a randomized phase II adjuvant study in patients with resected stage III melanoma investigating a personalized neoantigen mRNA vaccine in combination with anti-PD-1. The study gave a clear signal of superiority for the vaccine plus anti-PD-1 in relapse-free and distant-metastasis-free survival but is not yet conclusive, and important questions remain.
Keywords
Humans, Melanoma, Cancer Vaccines/therapeutic use, Adjuvants, Immunologic, Adjuvants, Pharmaceutic, Skin Neoplasms
OAI-PMH
oai:serval.unil.ch:BIB_362339C5E2F1
DOI
10.1016/j.medj.2024.03.004
Pubmed
38614074
Web of science
001229173200001
Create date
19/04/2024 8:21
Last modification date
26/07/2024 6:02
Usage data